Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sub-Visible Particles: Impact On Therapeutic Proteins

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
New LyoLearn webinar to run on 27th June 2013.

SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation Pathways, Adverse Immunogenicity and Regulatory Expectations for Therapeutic Proteins'.

During the session, Dr. John Carpenter Professor of Pharmaceutical Sciences and Co-Director of the Center for Pharmaceutical Biotechnology, University of Colorado (USA), discusses key areas and presents the latest results from his research.

In addition, he will highlight the particle counting instruments that have been vital to the progress made to date.

Over the past several years there has been greatly increasing attention on sub-visible particles in therapeutic protein products.

Initially, much of the discussion and debate in the field has centred on the utility and need for quantifying particles smaller than 10 micron.

As appropriate instruments and quantitative methods have been developed, valuable progress has occurred in a wide range of drug development areas and more clearly defining critical quality attributes and regulatory expectations related to sub-visible particles.

SP Scientific's program of free educational webinars delivered by industry experts are devoted to lyophilization, freeze-drying and related topics.

LyoLearn webinars follow a 45-minute format for the presentations with a Q&A session immediately afterwards.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Methods for Evaluating Lyophilized Product
SP Scientific, a world leader in freeze drying technology, has announced a new LyoLearn webinar that will discuss standard methods for evaluating lyophilized products.
Tuesday, December 07, 2010
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!